BioSpace News Archive

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2022 and provides a business update.

Amber Specialty Pharmacy announces that it will begin dispensing TZIELD™ (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D.

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.

Invacare Corporation announced that its Board of Directors has named Geoffrey P. Purtill as President and Chief Executive Officer, roles that he has served on an interim basis since August 28, 2022.

Viracta Therapeutics, Inc. announced that the Compensation Committee of Viracta’s Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 90,000 shares of common stock.

Tenaya Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 22,613,307 shares of its common stock and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 6,236,693 shares of its common stock.

Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”) today announced the closing of an underwritten public offering in the United States (the “Offering”) of 641,026 American Depositary Shares (“ADSs”), each representing 180 ordinary shares of Bionomics, at a public offering price of US$7.80 per ADS.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2022.

Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) and CalciMedica Inc. (CalciMedica) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Skylight Health Group Inc. (TSXV:SLHG; OTCQX: SLHGF) (“Skylight Health” or the “Company”) today announces that the Company has been granted an extension by the TSX Venture Exchange (the “TSXV”) to complete the final tranche of the previously announced US$5 million financing in the form of convertible debentures (“Financing”) by no later than December 21, 2022.